{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:45:08Z","timestamp":1793850308467,"version":"4.6.1"},"reference-count":53,"publisher":"Impact Journals, LLC","issue":"98","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,12,14]]},"DOI":"10.18632\/oncotarget.26354","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T19:59:05Z","timestamp":1544817545000},"page":"37080-37096","source":"Crossref","is-referenced-by-count":156,"title":["A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models"],"prefix":"10.18632","volume":"9","author":[{"given":"Kaiming","family":"Sun","sequence":"first","affiliation":[{"name":"TESARO Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Mikule","sequence":"additional","affiliation":[{"name":"TESARO Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zebin","family":"Wang","sequence":"additional","affiliation":[{"name":"TESARO Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Poon","sequence":"additional","affiliation":[{"name":"TESARO Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparajitha","family":"Vaidyanathan","sequence":"additional","affiliation":[{"name":"Division of Cellular Medicine, School of Medicine, University of Dundee, Jacqui Wood Cancer Centre, Ninewells Hospital & Medical School, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Cellular Medicine, School of Medicine, University of Dundee, Jacqui Wood Cancer Centre, Ninewells Hospital & Medical School, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"TESARO Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Hanke","sequence":"additional","affiliation":[{"name":"TESARO Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"TESARO Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"TESARO Inc, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,12,14]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/356356a0","article-title":"Role of poly(ADP-ribose) formation in DNA repair","volume":"356","author":"Lindahl","year":"1992","journal-title":"Nature"},{"key":"2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bcp.2012.03.018","article-title":"The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art","volume":"84","author":"Dantzer","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","article-title":"The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets","volume":"39","author":"Kraus","year":"2010","journal-title":"Mol Cell"},{"key":"4","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.molcel.2015.10.032","article-title":"Structural basis of detection and signaling of DNA single-strand breaks by human PARP-1","volume":"60","author":"Neuhaus","year":"2015","journal-title":"Mol Cell"},{"key":"5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1042\/bj1850775","article-title":"Novel inhibitors of poly(ADP-ribose) synthetase","volume":"185","author":"Whish","year":"1980","journal-title":"Biochem J"},{"key":"6","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Ashworth","year":"2013","journal-title":"Clin Cancer Res"},{"key":"7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2174\/187152007781668715","article-title":"PARP inhibitor development for systemic cancer targeting","volume":"7","author":"Curtin","year":"2007","journal-title":"Anticancer Agents Med Chem"},{"key":"8","volume-title":"SEER Cancer Statistics Review","author":"Krapcho","year":"1975"},{"key":"9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Hartmann","year":"2011","journal-title":"Nature"},{"key":"10","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Mitchell","year":"2012","journal-title":"J Clin Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Scroggins","year":"2014","journal-title":"Clin Cancer Res"},{"key":"12","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Cantor","year":"2005","journal-title":"Cancer"},{"key":"13","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Gonzalez-Angulo","year":"2010","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Herman","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"15","first-page":"5329","article-title":"BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study","volume":"60","author":"Karlan","year":"2000","journal-title":"Cancer Res"},{"key":"16","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"D'Andrea","year":"2015","journal-title":"Cancer Discov"},{"key":"17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Ashworth","year":"2009","journal-title":"EMBO Mol Med"},{"key":"18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0092-8674(03)00930-9","article-title":"EMSY Links the BRCA2 pathway to sporadic breast and ovarian cancer","volume":"115","author":"Chia","year":"2003","journal-title":"Cell"},{"key":"19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","article-title":"Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity","volume":"74","author":"Assiotis","year":"2014","journal-title":"Cancer Res"},{"key":"20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.molcel.2010.12.005","article-title":"miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors","volume":"41","author":"Chowdhury","year":"2011","journal-title":"Mol Cell"},{"key":"21","doi-asserted-by":"publisher","first-page":"9247","DOI":"10.1074\/jbc.M114.551143","article-title":"Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors","volume":"289","author":"Karnitz","year":"2014","journal-title":"J Biol Chem"},{"key":"22","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Pommier","year":"2012","journal-title":"Cancer Res"},{"key":"23","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"M\u0105dry","year":"2016","journal-title":"N Engl J Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Spencer","year":"2014","journal-title":"Lancet Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1200\/jco.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J Clin Oncol"},{"key":"26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Pommier","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"27","doi-asserted-by":"publisher","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"de Bono","year":"2016","journal-title":"Sci Transl Med"},{"key":"28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","article-title":"High speed of fork progression induces DNA replication stress and genomic instability","volume":"559","author":"Bartek","year":"2018","journal-title":"Nature"},{"key":"29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Poirier","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"30","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1535-7163.MCT-15-0282","article-title":"Poly-ADP-Ribose polymerase as a therapeutic target in pediatric diffuse intrinsic pontine glioma and pediatric high-grade astrocytoma","volume":"14","author":"Hawkins","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"31","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1158\/1535-7163.Mct-15-0587","article-title":"PARP inhibitors sensitize ewing sarcoma cells to temozolomide-induced apoptosis via the mitochondrial pathway","volume":"14","author":"Fulda","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"32","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1038\/s41467-018-05031-9","article-title":"Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance","volume":"9","author":"Altmeyer","year":"2018","journal-title":"Nat Commun"},{"key":"33","unstructured":"Pharmacology Noc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206162Orig1s000ClinPharmR.pdf."},{"key":"34","unstructured":"EMA Z. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/004249\/WC500239291.pdf."},{"key":"35","unstructured":"Review ONC. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206162Orig1s000ChemR.pdf."},{"key":"36","unstructured":"EMA O. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003726\/WC500180154.pdf."},{"key":"37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00280-017-3455-x","article-title":"Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients","volume":"81","author":"Beijnen","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"38","unstructured":"label O. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208558s000lbl.pdf."},{"key":"39","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10637-012-9922-7","article-title":"Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery","volume":"31","author":"Dixon","year":"2013","journal-title":"Invest New Drugs"},{"key":"40","unstructured":"NDA pharmacology O. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206162Orig1s000PharmR.pdf."},{"key":"41","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Tannock","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"42","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/jps.23952","article-title":"PARP Inhibitors as P-glyoprotein substrates","volume":"103","author":"Stordal","year":"2014","journal-title":"J Pharm Sci"},{"key":"43","unstructured":"label N. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208447lbl.pdf."},{"key":"44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/00498254.2016.1241449","article-title":"assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib","volume":"47","author":"Swaisland","year":"2017","journal-title":"Xenobiotica"},{"key":"45","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Ashworth","year":"2005","journal-title":"Nature"},{"key":"46","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Helleday","year":"2005","journal-title":"Nature"},{"key":"47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-014-1447-9","article-title":"Brain metastasis from ovarian cancer: a systematic review","volume":"119","author":"Jabbari","year":"2014","journal-title":"J Neurooncol"},{"key":"48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.18388\/abp.2002_3768","article-title":"Recognition and repair of DNA-cisplatin adducts","volume":"49","author":"Blasiak","year":"2002","journal-title":"Acta Biochim Pol"},{"key":"49","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.dnarep.2007.06.002","article-title":"Double-strand breaks induce homologous recombinational repair of interstrand cross-links via cooperation of MSH2, ERCC1-XPF, REV3, and the Fanconi anemia pathway","volume":"6","author":"Legerski","year":"2007","journal-title":"DNA Repair (Amst)"},{"key":"50","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Ellard","year":"2018","journal-title":"Ann Oncol"},{"key":"51","doi-asserted-by":"publisher","first-page":"LB","DOI":"10.1158\/1538-7445.AM2018-LB-273","article-title":"Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles","volume":"78","author":"Riches","year":"2018","journal-title":"Cancer Res"},{"key":"52","doi-asserted-by":"publisher","first-page":"7170","DOI":"10.1021\/jm901188v","article-title":"Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors","volume":"52","author":"Roscilli","year":"2009","journal-title":"J Med Chem"},{"key":"53","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Smith","year":"2016","journal-title":"Br J Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T20:05:01Z","timestamp":1589054701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,14]]},"references-count":53,"journal-issue":{"issue":"98","published-print":{"date-parts":[[2018,12,14]]}},"alternative-id":["26354","30647846"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.26354","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,14]]}}}